Definitive results: IL-2 does not benefit HIV-infected patients. Interleukin-2 improves CD4-cell recovery in patients on antiretroviral therapy, but that benefit does not translate into lower risks for disease or death.
Hicks
Charles B
CB
D019380:Anti-HIV Agents / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D015658:HIV Infections / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use*; D012307:Risk Factors
D019380:Anti-HIV Agents; D007376:Interleukin-2